Danaher lifts annual profit forecast on pharma demand, China recovery
Danaher, which provides tools and technologies that help pharmaceutical companies develop and make drugs, said demand from the industry remains strong, with robust number of clinical trials and therapies under development.
CEO Rainer Blair said that patents expiring soon for several high-volume therapies is also driving demand. Danaher expects high single-digit long-term growth for its bioprocessing unit.
"Monoclonal antibodies, which comprise more than 75% of our bioprocessing revenues remain the largest investment area for our customers," Blair said.
Revenues in China, about 12% of total sales, remained pressured due to Chinese government policies such as volume-based procurement and reimbursement changes.
But the company said its China business, barring diagnostics, is improving, as government stimulus boosts pharma and biotech industries.
Danaher's current exposure to proposed tariffs stands at "a couple hundred million dollars," down from previous estimates, a company executive told analysts on a call.
Still, Danaher flagged that demand from academic and government sectors remained soft due to uncertainty around research funding, while clinical diagnostics and applied markets stayed stable.
Evercore analyst Vijay Kumar said Danaher has delivered a "steady print" of results, and that improving trends in China and a potential bioprocessing recovery in 2026 could boost growth.
The company now forecasts annual adjusted profit per share of $7.70 to $7.80, up from its previous projection of $7.60 to $7.75.
Danaher expects third-quarter revenue to rise at a low-single-digit rate from a year earlier.
Second-quarter sales came in at $5.94 billion, surpassing analysts' estimates of $5.84 billion, according to data compiled by LSEG.
Separately, Danaher announced that Matthew Gugino will be succeeding long-time CFO Matthew McGrew, effective February 28, 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
5 hours ago
- BBC News
China dey offer parents $1,500 to encourage dem to born more children
Dem dey offer parents in China 3,600 yuan (£375; $500) a year for each of dia children under di age of three in di goment first nationwide subsidy wey aim to boost birth rates. Di kontri birth rate son dey fall, even afta di ruling Communist Party bin abolish di controversial one-child policy almost a decade ago. Di handouts go help around 20 million families wit di cost of raising children, according to state media. Several provinces across China get piloted some form of pay outs to encourage pipo to have more children as di world second largest economy face a looming demographic crisis. Di scheme, wey dem announce on Monday, dey offer parents a total of up to 10,800 yuan per child. Di policy dey applied retroactively from di start of dis year, Beijing state broadcaster CCTV tok. Families wit children wey dem born between 2022 and 2024 fit also apply for partial subsidies. Di move follow efforts by local goments to boost birth rates in China. In March, Hohhot - a city in di northern region of China - begin offer residents up to 100,000 yuan per baby for couples wit at least three children. Shenyang, a city northeast of Beijing, dey offer 500 yuan a month to local families wit a third child under three. Last week, Beijing dey also urged local goments to draft plans to implement free preschool education. Di kontri dey among di world most expensive places to have children, in relative terms, according to a study by China-based YuWa Population Research Institute. To raise a child to di age of 17 in China dey cost an average of $75,700, di study find. In January, official figures show say China population bin fall for a third year in a row in 2024. China bin record 9.54 million babies born in 2024, according to di National Bureau of Statistics. Dat mark a slight increase from di year bifor but di kontri overall population continue to shrink. Di kontri 1.4 billion population also dey age fast, add to Beijing demographic concerns.
The Independent
5 hours ago
- The Independent
Sri Lanka visas to be made free for UK tourists
Sri Lanka has announced plans to waive visa fees for British travellers in a bid to boost tourism. Foreign Minister Vijitha Herath reportedly confirmed that tourists from 33 new countries, including the UK, will be able to visit the island without paying visa fees at the Hotel Show Colombo 2025 on Friday (25 July). Travellers from the US, Germany, the United Arab Emirates and Australia will also be able to enter without paying visa fees, reported Travel + Leisure Asia. Mr Herath added that Sri Lanka 's government face an annual loss of up to £50m by waiving the visa fees. However, the minister expected higher tourist footfall from the free visas to make up for the loss in economic gains. According to a government press release, Mr Herath said that Sri Lanka's tourism industry is 'steadily progressing day by day', with the tourism sector expected to become a 'key contributor' to strengthening the national economy. He said: 'We have stabilised the economy, and through policy changes in tourism, we aim to ensure steady growth in arrivals.' Travellers from seven countries – China, India, Indonesia, Russia, Thailand, Malaysia and Japan – have had a visa fee waiver to enter the South Asian country since September 2024, following a trial phase in 2023. British passport holders currently have to apply for a 30-day tourist visa with a $50 (£37.50) fee to visit Sri Lanka. According to the Sri Lanka Tourism Development Authority (SLTDA), Sri Lanka welcomed 2,053,465 tourists in 2024. Of these, the island hosted the most Indian, Russian and British travellers. The start date for free visa entry is unknown; however, it is expected that eligible travellers will still need to apply for an Electronic Travel Authorisation (ETA) in advance, free of charge. The Independent has contacted Sri Lanka's Ministry of Tourism and the Sri Lanka Tourism Development Authority for comment.
Reuters
5 hours ago
- Reuters
Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
COPENHAGEN, July 29 (Reuters) - Obesity drugmaker Novo Nordisk ( opens new tab on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly (LLY.N), opens new tab. Novo shares have fallen sharply over the past year. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement. "This is related to lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO (International Operations) markets," it said. Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13%-21% forecast range. It also lowered its operating profit growth estimate to 10%-16%, from 16-24% previously. Sales rose 18% year-on-year in both the second quarter and the first half of the year, Novo said. Its operating profit increased by 40% in the April-June quarter and by 29% in the first half, the company added. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company in 2024, peaking at about 615 billion euros, but the value has since fallen by more than half. CEO Lars Fruergaard Jorgensen was ousted in May by Novo and its controlling shareholder, the Novo Nordisk Foundation, but will remain in his position until a successor is appointed. The company is scheduled to release full second-quarter earnings on August 6.
